"Federal officials are wrestling with a decision that could go a long way toward determining the future of the controversial new Alzheimer’s drug, Aduhelm, and whether significant numbers of patients use it."

"A controversial new drug for Alzheimer’s disease, the first in nearly 20 years, was approved in the US on Monday, which will trigger pressure to make it available worldwide in spite of mixed evidence over its efficacy."

>"There has been controversy around aducanumab, which targets the cause rather than the symptoms."

Participants with the disease still declined, but much more slowly than those receiving a placebo, investigators say.

Mental activity during the day produces buildup of beta-amyloid plaque, the protein known to play a role in Alzheimers disease. Sleeping cleanses the brain of this buildup, but poor sleep quality means less of this cleansing effect.